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In Brief
Analyses of human monoclonal
antibodies against the Plasmodium
falciparum protein PfRH5 identify a
subset of non-neutralizing antibodies that
synergize with a repertoire of other
neutralizing antibodies by slowing the
ability of malaria-causing parasites to
invade red blood cells.
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The Plasmodium falciparum reticulocyte-binding
protein homolog 5 (PfRH5) is the leading target
for next-generation vaccines against the disease-
causing blood-stage of malaria. However, little is
known about how human antibodies confer func-
tional immunity against this antigen. We isolated
a panel of human monoclonal antibodies (mAbs)
against PfRH5 from peripheral blood B cells from
vaccinees in the first clinical trial of a PfRH5-based
vaccine. We identified a subset of mAbs with
neutralizing activity that bind to three distinct sites
and another subset of mAbs that are non-func-
tional, or even antagonistic to neutralizing anti-
bodies. We also identify the epitope of a novel
group of non-neutralizing antibodies that signifi-
cantly reduce the speed of red blood cell invasion
by the merozoite, thereby potentiating the effect
of all neutralizing PfRH5 antibodies as well as
synergizing with antibodies targeting other malaria
invasion proteins. Our results provide a roadmap
for structure-guided vaccine development to
maximize antibody efficacy against blood-stage
malaria.INTRODUCTION
Malaria, responsible for some 435,000 deaths annually, is the
biggest parasitic killer in the world today with Plasmodium
falciparum accountable for the vast majority of these deaths216 Cell 178, 216–228, June 27, 2019 ª 2019 The Author(s). Publishe
This is an open access article under the CC BY license (http://creative(World Health Organization, 2018). Existing drugs and insecti-
cides are effective control measures but require sustained and
expensive investment to deploy and are threatened by the
emergence of resistance. It is therefore widely accepted that
an efficacious antimalarial vaccine, engendering adaptable
and durable immunity, will be a key factor in driving this dis-
ease toward elimination and ultimate eradication. However,
this has proved challenging, and efforts to generate vaccines
that target the invasive merozoite in the disease-causing
blood-stage of malaria infection have, to date, not been suc-
cessful (Draper et al., 2018). Previously, the advancement of
leading blood-stage subunit vaccine candidates has been
impeded by redundant invasion pathways (Wright and Rayner,
2014), considerable sequence polymorphism in target anti-
gens (Takala et al., 2009), and the elicitation of antibody re-
sponses in human vaccinees of insufficient magnitude and/
or breadth for effective neutralization (Draper et al., 2018).
This has raised the imperative to identify new conserved and
essential vaccine immunogens, to discover the most effective
epitopes of these immunogens for protective human anti-
bodies and to design molecules that will elicit these antibodies
to produce the most effective immune response.
Central to the symptomatic blood-stage of malaria infection is
the cyclical infection of host red blood cells (RBC) by the mero-
zoite form of the parasite. A fundamental and non-redundant
event in this process is the binding of P. falciparum reticulo-
cyte-binding protein homolog 5 (PfRH5) on the merozoite to its
host RBC receptor basigin (BSG) (Crosnier et al., 2011). Although
the precise function of PfRH5 is not known, it is linked to calcium
influx into the erythrocyte, followed by cytoskeleton remodeling
and is necessary for establishing a tight junction between para-
sites and RBCs (Weiss et al., 2015; Volz et al., 2016). Invasion is
accompanied by an N-terminal processing event of unknown
function, which trims PfRH5 from 60 kDa to 45 kDa (Baumd by Elsevier Inc.
commons.org/licenses/by/4.0/).
et al., 2009). PfRH5 associates with other merozoite surface pro-
teins to form an essential (Volz et al., 2016) invasion complex
including cysteine-rich protective antigen (PfCyRPA) (Reddy
et al., 2015), PfRH5-interacting protein (PfRipr) (Chen et al.,
2011), and glycosylphosphatidylinositol (GPI)-linked PfP113
(Galaway et al., 2017).
Several additional attributes of PfRH5 make it an attractive
vaccine candidate. Despite its uncommon protein fold (Wright
et al., 2014; Chen et al., 2014), PfRH5 can be expressed as a
soluble recombinant protein in several systems including
mammalian HEK293 cells (Crosnier et al., 2011), insect cells
(Chen et al., 2014; Hjerrild et al., 2016), and E. coli following
protein engineering (Campeotto et al., 2017). Furthermore,
low levels of antibodies elicited by repeated natural infection
(Douglas et al., 2011) suggest that neutralizing antibodies
that target PfRH5 in naturally acquired responses are rare.
Low natural immune pressure, coupled with functional con-
straints linked to BSG binding (Wanaguru et al., 2013), likely
account for the limited sequence diversity of PfRH5 (Manske
et al., 2012). Blood-stage malaria vaccinology benefits from
the use of an established in vitro assay of growth inhibition
activity (GIA) (Miura et al., 2009) that correlates with vaccine-
induced (as opposed to naturally acquired) protection in
non-human primate (NHP) malaria infection models (Singh
et al., 2006; Mahdi Abdel Hamid et al., 2011; Douglas
et al., 2015) and successfully predicts protection against
P. falciparum in a humanized mouse model and Aotus mon-
keys (Foquet et al., 2018; Douglas et al., 2019). In this assay,
PfRH5-specific immunoglobulin G (IgG) antibodies are effec-
tive against all P. falciparum parasite strains and isolates
tested in preclinical settings (Douglas et al., 2011; Williams
et al., 2012; Bustamante et al., 2013; Reddy et al., 2014).
Nevertheless, a combination of in vitro growth inhibition
studies and the Aotus monkey in vivo challenge trials suggest
that high concentrations of PfRH5-specific polyclonal IgG
(>300 mg/mL) are likely needed for effective immunity. Such
antibody levels will be challenging to achieve and sustain by
human-compatible vaccination regimens (Payne et al., 2017)
and to date, no human trial of a blood-stage malaria vaccine
has achieved the predicted threshold of clinical efficacy
(>60% GIA at a 1:4 serum dilution) (Singh et al., 2006; Douglas
et al., 2015). However, in recent years, rational structure-
informed vaccine design strategies have been developed to
address this challenge. These approaches immuno-focus vac-
cine-induced responses, specifically seeking to elicit the most
protective antibodies (McLellan et al., 2011; Correia et al.,
2014; Pierce et al., 2017). Understanding the key protective
epitopes on PfRH5 recognized by human IgG is likely to allow
similar approaches to be used to reduce the required specific
polyclonal antibody (pAb) concentration to tractable levels.
Here, we examine a panel of human monoclonal antibodies
(mAbs) to PfRH5, isolated from the first clinical trial of a
PfRH5-based vaccine (Payne et al., 2017), to define critical
mAb epitopes in atomic detail. Furthermore, we explore the
functional interplay between classes of mAbs likely to be con-
tained in pAb targeting PfRH5 following vaccination and high-
light the implications of this for rationally designed next-gener-
ation blood-stage malaria subunit vaccines.RESULTS
Vaccine-Induced Human mAbs to PfRH5
Anti-PfRH5 mAbs were isolated from single-cell-sorted plas-
mablasts of immunized volunteers enrolled in a first-in-human
Phase Ia clinical trial of a PfRH5-based vaccine delivered using
recombinant chimpanzee adenovirus and poxvirus viral-vec-
tors (Figure S1A) (Payne et al., 2017). Variable region (VR)-cod-
ing genes were isolated by RT-PCR and PCR and cloned into a
human IgG1 scaffold. Cognate heavy-chain and light-chain
plasmids were co-transfected in HEK293 cells, and PfRH5-
specificity was confirmed by supernatant reactivity to full-
length PfRH5 protein comprising amino acids E26–Q526
(PfRH5FL) by ELISA. Seventeen genetically distinct mAbs
were isolated (Figure 1A). Alignment with themost similar germ-
line VR gene segment alleles in IgBLAST (Ye et al., 2013) re-
vealed little non-germline sequence, suggesting that PfRH5 is
readily recognized with high affinity by germline B cell receptors
in humans. The monovalent binding affinity of each mAb was
assessed by surface plasmon resonance (SPR), with anti-
PfRH5 mouse or chimeric (c) mAbs c2AC7, c4BA7, c9AD4,
and QA1 included because of their extensive previous charac-
terization (Douglas et al., 2014; Wright et al., 2014) (Figures 1B
and S1B). Affinities were in the low nanomolar to high picomo-
lar range.
The effect of PfRH5 polymorphism on mAb recognition was
determined by measuring binding to recombinant PfRH5FL var-
iants, each carrying one of the five most common naturally
occurring amino acid substitutions (Figure 1C). In each case,
except for C203Y, the generated PfRH5FL variants carried the
minor allele. All global minor allele frequencies were below
0.19 (MalariaGEN v4.0) (Manske et al., 2012). The only mAb to
show significant differential binding was R5.017, for which
binding was reduced by S197Y. Only one human- and one
mouse-derived mAb (R5.007 and c4BA7) were able to bind
heat-treated PfRH5FL protein, suggesting a linear epitope (Fig-
ure 1D). In addition, a dot blot against P. falciparum 3D7 clone
in vitro culture supernatant showed all mAbs to bind parasite-
expressed PfRH5 (Figure S1C) that consists of a processed
45 kDa form (Baum et al., 2009; Chen et al., 2011).
The Neutralizing Capacity of Human mAbs
Binding PfRH5
To characterize the ability of the humanmAbs to blockmerozoite
entry into RBCs, they were tested for in vitro GIA against 3D7
clone P. falciparum. An initial screen was carried out at high con-
centration, grouping the mAbs into three categories: ‘‘GIA-high’’
(GIAR75%), ‘‘GIA-low’’ (75%>GIA > 25%), and ‘‘GIA-negative’’
(GIA%25%) (Figure 2A). Dilution curves of GIA-high mAbs were
made against 3D7 clone parasites to assess potency (Figure 2B).
The twomost potent mAbs (R5.016 and R5.004) had EC50 values
comparable to the most potent anti-merozoite mouse-derived
mAbs previously described (Douglas et al., 2014; Ord et al.,
2014). A strong correlation was also observed between the asso-
ciation-rate (Kon) of the neutralizing antibodies (nAb) and GIA
(Figure S2), indicating a limited time window for mAb-PfRH5
binding in the context of merozoite invasion (Douglas et al.,
2014; Saul, 1987). GIA assays were repeated against sixCell 178, 216–228, June 27, 2019 217
mAb VR donor Chain Allele usage
Germline 
change 
(%)
Heavy IGHV1-18*04, IGHD4-17*01, IGHJ5*02 1.0 (3/296)
Light IGKV1D-16*01, IGKJ4*01 1.1 (3/278)
Heavy IGHV3-49*04, IGHD1-20*01, IGHJ5*02 0.3 (1/301)
Light IGLV3-21*02, IGLJ2*01,IGLJ3*01 0.3 (1/288)
Heavy IGHV1-69*01, IGHD3-22*01, IGHJ4*02 2.4 (7/293)
Light IGKV3-11*01, IGKJ2*01 2.1 (6/287)
Heavy IGHV1-69*01, IGHD3-16*01, IGHJ3*02 2.4 (7/295)
Light IGLV1-44*01, IGLJ3*02 1.0 (3/294)
Heavy IGHV4-39*01, IGHD6-13*01, IGHJ4*02 2.7 (8/298)
Light IGLV3-21*01, IGLJ2*01/IGLJ3*01 2.1 (6/290)
Heavy IGHV3-7*02, IGHD3-16*01, IGHJ5*02 1.0 (3/292)
Light IGKV4-1*01, IGKJ1*01 3.0 (9/300)
Heavy IGHV3-33*01, IGHD3-10*01, IGHJ4*02 2.4 (7/292)
Light IGKV1-39*01, IGKJ4*01 2.1 (6/287)
Heavy IGHV3-23*04, IGHD3-22*01, IGHJ4*02 1.4 (4/295)
Light IGLV1-40*01, IGLJ3*02 1.0 (3/297)
Heavy IGHV3-7*03, IGHD6-25*01, IGHJ6*02 1.4 (4/295)
Light IGLV3-21*02, IGLJ2*01/IGLJ3*01 1.1 (3/285)
Heavy IGHV7-4-1*02, IGHD3-22*01, IGHJ4*02 1.0 (3/293)
Light IGLV3-21*02, IGLJ3*02 1.4 (4/289)
Heavy IGHV4-39*01, IGHD3-3*01, IGHJ4*02 1.7 (5/297)
Light IGKV3-11*01, IGKJ3*01 1.8 (5/283)
Heavy IGHV3-9*01, IGHD2-21*02, IGHJ4*02 1.4 (4/296)
Light IGLV1-44*01, IGLJ3*02 1.4 (4/294)
Heavy IGHV1-2*04, IGHD3-10*01, IGHJ6*02 1.7 (5/295)
Light IGLV3-21*01, IGLJ2*01/IGLJ3*01 4.2 (12/288)
Heavy IGHV1-18*01, IGHD3-9*01, IGHJ6*02 1.7 (5/296)
Light IGKV1-5*03, IGKJ2*01 3.6 (10/281)
Heavy IGHV1-69*02, IGHD5-24*01 , IGHJ6*02 3.8 (11/291)
Light IGLV1-40*01, IGLJ3*02 0.3 (1/299)
Heavy IGHV3-33*01, IGHD3-22*01, IGHJ4*02 1.7 (5/295)
Light IGKV1-39*01, IGKJ1*01 2.5 (7/284)
Heavy IGHV4-31*01, IGHD3-3*01, IGHJ4*02 1.3 (4/298)
Light IGKV3-20*01, IGKJ2*04 1.7 (5/290)
Heavy IGHV5-15*02, IGHD2-4*01, IGHJ1*01 3.1 (9/295)
Light IGKV3-1*01, IGKJ1*01 3.4 (10/296)
Heavy IGHV1-87*01, IGHD1-3*01, IGHJ4*01 3.1 (9/292)
Light IGKV4-91*01, IGKJ4*01 2.1 (6/288)
Heavy IGHV5-15*02, IGHD2-4*01, IGHJ1*01 2.0 (6/295)
Light IGKV3-1*01, IGKJ1*01 3.4 (10/296)
Heavy IGHV5-4*02, IGHD2-1*01, IGHJ4*01 3.4 (10/296)
Light IGKV3-7*01, IGKJ2*01 2.4 (7/296)
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Figure 1. Description and Binding Characteristics of Anti-PfRH5 mAbs
(A) Genetic lineage of variable regions from PfRH5-specific mAbs and their donor origin, showing percentage of nucleotide substitutions relative to germline.
(B) Iso-affinity plot showing kinetic rate constants for binding of mAbs to PfRH5FL as determined by SPR. Diagonal dotted lines represent equal affinity at
equilibrium.
(C) Real-time analysis by BLI of mAb binding to PfRH5FL variants with the five most common naturally occurring amino acid substitutions. Bars represent fold-
change compared to wild type PfRH5FL (3D7 sequence) binding.
(D) Assessment of binding of PfRH5-specific mAbs to heat-treated PfRH5FL protein by ELISA. Bars show the mean and error bars show the SEM (n = 2).
See also Figure S1.heterologous strains and isolates originating from diverse
geographical locations (Figure 2C), which contain all five of the
most common PfRH5 polymorphisms (Figure 2D). This revealed
some strain-dependent differences in anti-PfRH5 mAb potency,
albeit with very similar hierarchies. Indeed, GB4 was more easily
neutralized by all mAbs relative to 3D7, while M-Camp was less
easily neutralized. The reason for these in vitro differences, and
their relevance to in vivo neutralization, remains uncertain, as
the M-Camp isolate was as susceptible as 3D7 to PfRH5 vac-
cine-induced polyclonal human IgG from the same origin as
the mAbs (Payne et al., 2017). One notable exception was
R5.017, which lacked efficacy against the FVO strain and218 Cell 178, 216–228, June 27, 2019Cp845 isolate. Only these two parasites carry the S197Y poly-
morphism (Figure 2D) that reduces binding of R5.017 (Figure 1C).
Clustering of PfRH5-Specific mAbs into Functional
Groups
To better understand the relationship between mAb binding site
and function, mAbswere tested in pairs for simultaneous binding
to monobiotinylated PfRH5FL by Bio-Layer Interferometry (BLI)
(Figures S3A and S3B; Table S1). This defined seven distinct
epitope bins, each containing mAbs that bind overlapping epi-
topes (Figure 3A). The resulting bins strongly correlated with
GIA, with the red, blue, and olive bins containing the most potent
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3D7 Figure 2. Growth Inhibitory Properties of
Human PfRH5-Specific mAbs
(A) In vitro GIA of each mAb tested at 3 mg/mL
against 3D7 clone P. falciparum. Bars are color-
coded to reflect potency (‘‘GIA-high’’ [R75%] in
green, ‘‘GIA-low’’ [75% > GIA > 25%] in gray and
‘‘GIA-negative’’ [%25%] in black).
(B) In vitro GIA dilution series against the 3D7
reference clone. EC50 values were determined by
interpolation after fitting data to a four-parameter
dose-response curve.
(C) In vitro GIA dilution series of GIA-high mAbs
against heterologous parasite laboratory lines and
isolates.
(D) Amino acids at the five most common poly-
morphic sites of PfRH5 for the seven parasite lines.
Deviations from the 3D7 reference sequence are
highlighted in red. All GIA data points are the mean
of duplicate wells, with each dataset fitted to a
four-parameter dose-response curve.
See also Figure S2.anti-PfRH5 mAbs and the purple, yellow, green, and orange bins
exclusively containing GIA-low or GIA-negative antibodies (Fig-
ure 3B). The epitope bins also proved successful in clustering
together mAbs whose binding blocked in vitro interactions be-
tween PfRH5FL and the invasion complex protein PfCyRPA or
the PfRH5 receptor BSG (Figures 3C, S3C, and S3D). Indeed,
the blue and olive bins contained all mAbs that block BSG bind-
ing by both SPR and AVEXIS, while the purple, yellow, and or-
ange bins contained all the mAbs that block PfCyRPA binding
in the SPR assay and the most potent blockers in the
AVEXIS assay. The lack of PfP113 blockade (Figure 3D) was
unsurprising because no mAbs bound the PfRH5 N-terminal re-
gion (PfRH5Nt), which includes amino acids K33–K51 reported
as the minimal PfP113 binding region (Galaway et al., 2017)(Figures S3E and S3F). Collectively, these
data highlight the vicinity of the BSGbind-
ing site, and not the PfCyRPA binding
site, as the key target of growth inhibitory
mAbs, and show that the most potent
nAbs bind to these regions with the high-
est association-rates (Figure S2).
All Major Neutralizing PfRH5
Epitopes Are within the Truncated
PfRH5DNL Protein
Previous crystallization of PfRH5 was
aided by removal of two sections of disor-
dered sequence resulting in a truncation
lacking 188 of 526 residues (M1-Y139
and N248-M296), termed PfRH5DNL
(Wright et al., 2014). Notably this trun-
cated protein lacks PfRH5Nt (including
the minimal PfP113 binding region) and
thus a potential site for antibody-medi-
ated neutralization. Interestingly, all
GIA-high mAbs and two of three GIA-
low mAbs bound PfRH5DNL, suggestingthat this construct contains the major neutralizing epitopes (Fig-
ure 3D). Only R5.007 and c4BA7 were unable to bind this
construct. Their binding site was mapped by ELISA to the inter-
nal disordered loop and not the N-terminal region, using an array
of overlapping peptides. Both mAbs bound the same linear
PfRH5 peptides (amino acids Y242–D261) (Figure S3E), consis-
tent with their recognition of heat-treated PfRH5FL protein (Fig-
ure 1D). Furthermore, no mAbs bound recombinant PfRH5Nt by
ELISA (amino acids F25–K140) (Figure S3F).
We next assessed the effect of PfRH5FL or PfRH5DNL pro-
teins on the GIA of total polyclonal IgG purified from sera of
PfRH5FL-immunized human vaccinees (Payne et al., 2017).
The in vitro GIA could be reversed by adding 0.5 mM of recombi-
nant PfRH5FL or PfRH5DNL into the IgG sample. GIA of IgG fromCell 178, 216–228, June 27, 2019 219
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Figure 3. Epitope Binning Reveals that All Relevant Neutralizing Epitopes Lie within PfRH5DNL
(A) Epitope bins determined by BLI from a matrix of sequential PfRH5FL-binding assays for different mAbs, with data used to construct these bins in Figure S3A
and Table S1.
(legend continued on next page)
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all seven vaccinated volunteers was completely reversed
following the addition of either PfRH5 variant protein (Figure 3E),
a finding that also repeated when using purified IgG from rabbits
immunized with PfRH5FL (data not shown). Notably, vaccine-
induced IgG against PfRH5Nt was previously reported in the
serum of these volunteers by ELISA (Payne et al., 2017), sug-
gesting minimal or no contribution of these responses to overall
GIA. To confirm that PfRH5DNL vaccination can also elicit anti-
body to the most functionally relevant neutralizing epitopes pre-
sent in PfRH5FL, two groups of rabbits were immunized with
equimolar doses of PfRH5FL or PfRH5DNL. The resulting puri-
fied IgG showed comparable potency in the GIA assay across
both groups, indicating that no major neutralizing epitopes are
lost in PfRH5DNL (Figures 3F and 3G). Passive transfer of
PfRH5DNL-immunized rabbit IgG into humanized mice, carrying
human hepatocytes and erythrocytes and challenged by
P. falciparum-infected mosquito bites (Foquet et al., 2018), re-
sulted in a significant reduction of blood-stage parasite burden,
further serving to highlight that vaccine-induced IgG to this
PfRH5 truncation is sufficient to effectively retard or arrest
blood-stage parasitemia in vivo (Figure 3H). Analysis of PfRH5-
specific pAb concentrations in the serumof passively immunized
mice (Figure 3I) were consistent with the levels that led to control
of blood-stage parasitemia, but not sterilizing immunity, in
PfRH5FL-vaccinated Aotus monkeys (Douglas et al., 2015).
The rigid a-helical core of PfRH5, lacking PfRH5Nt, is thus likely
to contain all major neutralizing epitopes and is sufficient to repli-
cate the neutralizing effect of antibody raised to the full-length
PfRH5 antigen.
Identifying the Epitopes for Key Neutralizing mAbs
The binding modes of R5.016 and R5.004, the two most potent
known human anti-PfRH5 nAbs, were next determined by
X-ray crystallography. A crystal containing PfRH5DNL, one
R5.016 Fab fragment, and one R5.004 Fab fragment diffracted
to a resolution of 4.0 A˚ (Figure 4A; Table S2). High-resolution
structures of unbound R5.016 and R5.004 Fab fragment crystals
were also determined, with clear electron density observed for
all CDR loops in the bound states, facilitating determination of
the complex structure (Figure S4B; Table S2). The R5.004 and
R5.016 binding sites were corroborated in solution by
hydrogen-deuterium exchange mass spectrometry (HDX-MS)(B) Potency of anti-PfRH5 mAb invasion inhibition grouped by epitope bin. EC30
(C) The effect of mAbs on binding of PfRH5FL to BSG, PfCyRPA, and PfP113Nt
control. The colors used in (B) and (C) match those of the epitope bins in (A).
(D) Binding of anti-PfRH5 mAbs to PfRH5DNL by ELISA. Bars show the mean of
(E) GIA of purified total IgG from seven different PfRH5FL-vaccinated human vol
20 mg/mL, respectively). Bars show the mean of duplicate wells.
(F) GIA of purified total IgG from rabbits immunizedwith PfRH5FL or PfRH5DNL (n
measured by ELISA using a conversion factor determined by calibration-free co
(G) Comparison of EC50 for rabbit sera. EC50 values were determined for each r
response curve. Black horizontal bars represent the mean.
(H) Intravital luminescence signal of humanized mice infected with transgenic P.
nation or PfRH5DNL-vaccinated rabbit IgG at day (d)6 post-infection. Starting gro
Mice that died before the experiment endpoint (d13) were: one at d7 and one at d
and one at d6, one at d10 and one at d12 in the vaccinated IgG group. Individua
(I) Concentration time course of PfRH5-specific rabbit IgG in the passive transfe
points show the mean. All GIAs used 3D7 clone P. falciparum. All error bars sho(Figures 4B and S4A). R5.004 binds PfRH5 toward the tip of
the ‘‘kite-like’’ structure, contacting the N terminus of helix 4
and each of the three loops that link the converging helices at
this apex of PfRH5. These interactions are mediated by five of
the CDR loops of the antibody, with only L2 not participating (Ta-
ble S3). R5.016 binds predominantly to the N terminus of helix 2
of PfRH5. The major contact is mediated by the H3 loop, which
lies along the groove between helices 2 and 3. Additional interac-
tions are mediated by the H1, H2, and L2 loops (Table S3). While
the CDR loops of R5.004 are not altered upon binding (root-
mean-square deviation [RMSD] = 0.58 A˚ aligning 59/68 CDR
a-carbon atoms), four of the CDR loops of R5.016 (H3, L1, L2,
and L3) show significant rearrangement upon binding
(Figure S4C).
Superimposition of the R5.004 and R5.016 Fab fragment
structures on the structure of PfRH5DNL:BSG (PDB: 4U0Q) re-
veals major overlap between the binding sites of BSG and
R5.004 (Figure 4C). In contrast, of the two copies of BSG in the
PfRH5DNL:BSG structure (Wright et al., 2014), one overlaps
with R5.016 while one does not. This suggests that, while simul-
taneous binding is possible, the proximity of R5.016 to the BSG
binding site is likely to lead to steric occlusion in the context of
an intact IgG antibody and membrane attachment of both
components. In comparison to previously studied murine
mAbs, R5.016 shares much of its binding site with 9AD4, while
R5.004 binds to a distinct epitope which shows some overlap
with that of QA1 (Wright et al., 2014). Indeed, 9AD4 and QA1
compete for binding with R5.016 and R5.004, respectively (Fig-
ure 3A; Table S1). These data serve to further confirm the BSG
binding area and the helical face composed of helices 2
and 3 as two major sites of antibody-mediated neutralization
on PfRH5 and identify epitopes for nAbs that are close to human
germline and are readily elicited following vaccination.
Vaccine-Induced mAbs Can Antagonize the Effects of
Broadly Neutralizing mAbs
Having identified key neutralizing epitopes on PfRH5, we next
assessed the functional activity of combinations of mAbs that
bind similar epitopes yet have dissimilar neutralizing properties.
We noted that mAbs within the same epitope bin usually cross-
compete for binding while those from different epitope bins do
not. However, within pairs R5.001/R5.016, R5.008/R5.010, andvalues were interpolated from data in Figure 2B.
, as determined by SPR. Black bars show binding in the absence of mAb as a
4 replicate wells.
unteers alone or with 0.5 mM of PfRH5FL or PfRH5DNL protein (30 mg/mL and
= 6 rabbits per group). Concentrations of PfRH5FL-specific polyclonal IgGwere
ncentration analysis. Individual data points show the mean of triplicate wells.
abbit by interpolation after fitting the data from (F) to a four-parameter dose-
falciparum (NF54-luciferase) following passive transfer of 15 mg of pre-vacci-
ups were n = 2 for the PBS group and n = 4 for the IgG passive transfer groups.
13 in the PBS group, one at d9 and one at d12 in the pre-vaccination IgG group
l data points are connected by a line representing the mean.
r experiment shown in (H), as determined by ELISA binding to PfRH5FL. Data
w the SEM.
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Figure 4. Structures of R5.004 and R5.016 Epitopes
(A) Structure of PfRH5DNL bound to R5.004 and R5.016 Fab fragments. Insets show close-up views of epitopes.
(B) The top PfRH5 peptides protected in HDX-MS by R5.004mAb (blue) and R5.016mAb (red) binding, are highlighted on the structure of PfRH5DNL. Positions of
Fab fragments are overlaid as faded cartoons.
(C) Overlay of PfRH5DNL:BSG (PDB: 4U0Q, BSG in teal) with R5.004 Fab or R5.016 Fab structures at their respective binding sites in the
PfRH5DNL:R5.004:R5.016 structure.
See also Figure S4 and Tables S2 and S3.R5.010/R5.018, mAbs compete for binding to PfRH5 in vitro but
have differing neutralization properties (Figures 2A, 3B, and S3B;
Table S1). We therefore sought to assess the consequence of
mAb competition on neutralization. In the case of the R5.008/
R5.010 pair, the addition of R5.010 hampered the neutralizing
capacity of R5.008 (Figure 5A). However, the same was not
true for the R5.001/R5.016 and R5.010/R5.018 pairs, where no
significant difference was observed when testing the mixture of
twomAbs. These data show that antagonism can occur between
mAbs that bind distinct epitope regions on PfRH5, highlighting
the need to avoid the production of such antagonistic mAbs dur-
ing vaccination.
A Class of Non-neutralizing mAb Potentiates the Effect
of Antibodies that Bind PfRH5 and Other Merozoite
Proteins
Having observed one example of antagonism, we continued our
functional assessment of alternative mAb pairs that bind non-
overlapping epitopes on PfRH5 and which do not compete for
binding. Combinations of mAbs were tested in the GIA assay
to determine whether they can improve inhibition of invasion
either additively or synergistically (Williams et al., 2012). Remark-
ably, mAb R5.011 potentiated the inhibitory effect of all eight of
the most potent nAbs against 3D7 clone parasites, showing a
clear synergistic effect despite itself showing no neutralizing ca-
pacity when tested alone. This effect did not extend to GIA-low
mAbs R5.001 and R5.015 or any GIA-negative mAbs (Figure 5B222 Cell 178, 216–228, June 27, 2019and see Figure 2A). R5.011 shares an epitope bin with R5.014
and R5.010 (Figure 3A). R5.014 was also capable of potentiating
the effect of a nAb (tested here with R5.016). However,
combining R5.010 with R5.016 had no effect (Figure S5A).
The synergistic effect of mAb R5.011 was maintained using
either a nAb Fab fragment or a R5.011 Fab fragment, ruling out
mechanisms linked to IgG bivalency or the Fc domain (Fig-
ure S5C). Synergistic effects were also seen upon addition of
R5.011 mAb to polyclonal IgG from PfRH5-vaccinated human
volunteers (Figure 5C), as well as rabbits (Figure S5B), indicating
that this potentiating phenomenon is far from beingmaximized in
these naturally elicited vaccine-induced IgG.
Dilutions of nAb in the presence of a large excess of R5.011 re-
vealed the maximum possible synergistic effect. Under these
conditions, the EC80 of R5.016 is reduced from 500 mg/mL to
55 mg/mL, and a similar effect was seen for R5.004 (Figure 5D).
Furthermore, titrating R5.011 into several fixed concentrations of
nAb showed that the maximal potentiating effect is achieved
with 200 mg/mL of R5.011 (Figure S5D). The optimal ratio of
nAb:R5.011 across the concentration range was approximately
4:1, with nAb-biased ratios being more effective at lower con-
centrations and all ratios roughly equivalent at concentrations
above 100 mg/mL (Figure S5E).
We next explored whether the effect of R5.011 was
PfRH5-specific by assessing synergy with antibodies targeting
merozoite antigens involved in other steps of the RBC invasion
process (Weiss et al., 2015; Cowman et al., 2017). The addition
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Figure 5. Non-neutralizing mAb R5.011 Po-
tentiates the Growth Inhibitory Effect of
Anti-PfRH5 nAbs
(A) GIA of nAbs R5.008 (300 mg/mL), R5.016
(150 mg/mL), and R5.018 (400 mg/mL) alone
(colored data points) or in the presence of an
equimolar concentration of a mAb that blocks its
binding to PfRH5FL in vitro (gray data points).
(B) GIA of human anti-PfRH5 mAbs at 150 mg/mL
alone (colored data points) or in the presence of
150 mg/mL R5.011 (gray data points).
(C) GIA of total human IgG from five PfRH5FL-
vaccinated volunteers (1017, 1020, 2205, 2207,
and 2210) at 5 mg/mL, alone (red data points) in
the presence of 300 mg/mL of R5.011 or R5.003.
(D) GIA of a dilution series of mAbs R5.004,
R5.016, and R5.011 alone (blue, red, and green,
respectively) as well as a dilution series of the
R5.004 and R5.016 nAbs in the presence of an
excess of R5.011 (500 mg/mL) (gray) to determine
the maximal effect of R5.011. ‘‘Concentration of
test mAb’’ refers to the concentration of nAb in
mAb combinations.
(E) GIA of total IgG from rabbits immunized with
PfMSP1 (5 mg/mL, green), PfRH4 (10 mg/mL,
black), PfCyRPA (5 mg/mL, yellow), PfRipr
(10mg/mL, orange), or PfAMA1 (3.25mg/mL, pink)
with the addition of 300 mg/mL of R5.011 or R5.009
(gray data points). Concentrations were chosen to
achieve 30%–60% GIA in the absence of mAb.
All data points are the mean of 3 replicates and all
error bars show the SEM. Parasites usedwere 3D7
clone P. falciparum.
See also Figure S5.of R5.011 mAb to polyclonal IgG from rabbits or rats immunized
with PfRH4, PfCyRPA, PfRipr, and PfAMA1 leads to markedly
increased GIA, whereas its addition to anti-PfMSP1 IgG had no
effect (Figures 5E and S5F). These data suggest R5.011-like an-tibodies can act synergistically with other
functional antibodies targeting the PfRH5
invasion complex antigens as well as
other targets such as PfRH4 andPfAMA1,
whereas this effect is not observed for
antibodies targeting antigens that act
prior to merozoite reorientation, such as
PfMSP1.
We finally investigated whether R5.016
and R5.011 can be functionally combined
into a single molecule by producing a
bispecific dual variable domain immuno-
globulin (DVD-Ig) containing the variable
domains of R5.011 and R5.016. To
achieve comparable levels of growth
inhibition, a R5.016 + R5.011mAb combi-
nation required fewer molecules than for
R5.016 alone (Figure S5G). Furthermore,
approximately half the molar concentra-
tion of 1611 DVD-Ig is required to achieve
the same levels of GIA as the parentalR5.016 + R5.011 mAb combination, hinting to a bivalent binding
mode of this DVD-Ig molecule. To our knowledge, this
DVD-Ig shows the lowest reported EC80 for an anti-merozoite
antibody-like molecule. Because high levels of merozoiteCell 178, 216–228, June 27, 2019 223
Figure 6. Structure of PfRH5DNL in Complex with R5.011 and R5.016
(A) Crystal structure of PfRH5DNL bound to Fab fragments from R5.011 and R5.016. The top left inset shows a close-up of the R5.011 epitope. The bottom left
inset shows PfRH5 as a gray surface with the peptide most protected by R5.011 mAb in a HDX-MS assay in green. R5.011 is overlaid as a faded cartoon.
(B) Overlay of R5.004, R5.011 and R5.016 structures bound to PfRH5DNL.
See also Figure S6 and Tables S2 and S3.neutralization are known to be required for protection (Douglas
et al., 2015, 2019), the antibody EC80 or EC90 may prove to be
a more useful measure of efficacy than the more widely
used EC50.
Overall, these data identify R5.011 as a novel antimalarial mAb
that displays a new functionality by potentiating the effect of all
tested anti-PfRH5 nAbs and pAb, aswell as pAb directed against
other merozoite antigens, despite having no intrinsic neutralizing
properties when tested alone. This raises the critical importance
of inducing such antibodies in next-generation PfRH5-based
vaccination strategies.
The R5.011 Epitope Lies at the N Terminus of PfRH5DNL
To identify the R5.011 epitope, a crystal structure of PfRH5DNL
bound to one R5.011 Fab fragment and one R5.016 Fab
fragment was determined to a resolution of 3.6 A˚, with all
CDR loops clearly resolved (Figures 6A and S6D). A high-reso-
lution structure of unbound R5.011 Fab fragment was also
determined and used, together with structures of R5.016 Fab
fragment and PfRH5DNL, to provide model restraints (Table
S2). R5.011 binds PfRH5 primarily at the interface between
the disordered N terminus and the rigid a-helical core at resi-
dues Y155–L162, a finding also confirmed by HDX-MS (Figures
6A, lower left inset box, and S6A). Residues F144–N159 of
PfRH5 are variably ordered in different crystal structures but
are most frequently disordered (Wright et al., 2014; Chen
et al., 2014). R5.011 binds to these residues and constrains
and orders their conformation as they emerge from the a-heli-
cal core of PfRH5 (Figure S6B). All CDR loops except L3 con-
tact PfRH5, with the predominant interaction mediated by H3
(Table S3). Binding is accompanied by a major change in
the conformation of the H3 CDR loop of R5.011, which packs
against residues Y155–D162 (Figure S6C). The position of224 Cell 178, 216–228, June 27, 2019R5.016 in PfRH5DNL:R5.011:R5.016 is equivalent to that
in PfRH5DNL:R5.004:R5.016. Figure 6B shows an overlay
of R5.004, R5.011 and R5.016 Fab fragments bound to
PfRH5DNL, radiating in different directions, for comparison.
The structures revealed that the binding sites of R5.004 and
R5.016 are unaltered (<0.5 A˚ RMSD aligned over 39 and
30 a-carbon atoms, respectively) by R5.011 binding. Further-
more, the binding affinity and Kon of nAbs R5.004 and R5.016
for PfRH5 are unchanged by R5.011 binding (Figure S6E), dis-
missing structural allostery as a mechanism of anti-PfRH5 nAb
potentiation. Thus, R5.011 accesses an epitope largely devoid
of secondary structure at a new site on PfRH5.
R5.011 Potentiates Anti-merozoite nAbs by Increasing
the Time Required for Invasion
The ability of R5.011 to potentiate the activity of nAbs that bind to
various merozoite invasion proteins, together with the demon-
stration that antibody on-rate is a critical determinant of neutral-
izing efficacy, led us to hypothesize that this mAb may slow
down the invasion process, thus giving longer for the nAbs to
reach their binding sites. Indeed, live-cell imaging revealed that
the time taken for merozoites to invade RBC is significantly
longer (around 3-fold) in the presence of R5.011 versus a control
mAb targeting Ebolavirus (Figures 7A and S7A; Videos S1 and
S2) and versus non-neutralizing, non-potentiating anti-PfRH5
mAb R5.009 (Figure S7B). Concentrations of R5.016 around
the EC50 did not slow the invasion of those merozoites
which were able to invade, whereas high concentrations of
R5.016 blocked invasion altogether (Figure S7B; Video S3).
The observed delay is largely attributed to the phase of invasion
preceding merozoite penetration (Figures 7B and S7A), when
invasion ligands PfRH4, PfRH5, PfCyRPA, PfRipr, and PfAMA1
are thought to act. Therefore, R5.011 lengthens the exposure
AB
Figure 7. R5.011 Increases Parasite Invasion Time
(A) Total time for RBC invasion in the presence of R5.011 or an irrelevant
isotype-matched antibody control (a-EBOV).
(B) Time for early invasion (pre-penetration) and late invasion (penetration).
Data are presented as box-and-whiskers plots showing the interquartile range
and total range overlaid on individual data points. Solid black lines show the
mean for each group. 3D7 cloneP. falciparum parasites were used. BothmAbs
were used at 500 mg/mL and 21 and 22 invasion events were recorded for
a-EBOV and R5.011, respectively. ****p < 0.0001; n.s., non-significant.
See also Figure S7 and Videos S1, S2, and S3.window of critical merozoite targets to nAbs by slowing RBC
entry, thus increasing their opportunity to bind and prevent
invasion.
DISCUSSION
Here, we determine the features of a desirable human antibody
response to the most advanced blood-stage malaria vaccine
candidate antigen, PfRH5, relating the functions of mAbs to
their binding sites. We describe different classes of anti-PfRH5mAb: highly neutralizing mAbs, seemingly inert mAbs, antago-
nistic mAbs, and a novel class of synergistic non-neutralizing
mAbs with the unexpected ability to potentiate the invasion-
blocking properties of many nAbs, including those targeting
other invasion proteins, by slowing invasion.
Three epitope bins contained GIA-high mAbs: red, blue, and
olive. Those in the blue and olive bins function by directly block-
ing BSGbinding, as shown by in vitro SPR and AVEXIS assays as
well as X-ray crystallography data for mAb R5.004. In contrast,
mAb R5.016 (from the more potent red bin) and BSG can simul-
taneously bind PfRH5 in solution and mAbs from the red epitope
bin interfere little with binding to BSG, PfCyRPA, or PfP113. The
most likely explanation for the efficacy of R5.016 is the proximity
of its binding site on PfRH5 to the BSG binding site. With both
PfRH5 and BSG constrained through attachment to their
cognate membrane, R5.016 and other similar antibodies are
likely to act by preventing PfRH5 from binding to BSG. If so, their
improved potency over the BSG-blocking nAbs could be due to
increased ease of epitope access on merozoite-bound PfRH5.
The fact that antibody association-rate, as opposed to the
often-measured affinity, emerged as a key indicator of antibody
potency implies that highly dynamic processes are involved in
invasion. This is supported by our discovery that a 3-fold
lengthening of invasion time correlates with a potentiation of
nAb activity. An importance for high antibody on-rates has
been noted before for certain viral pathogens (Bates et al.,
2014), nevertheless, this is an often-neglected parameter that
is highly relevant to blood-stage malaria vaccine design.
In addition, we present our discovery of a novel class of anti-
body that potentiates the effects of nAbs against various mero-
zoite surface proteins by significantly slowing invasion. This
demonstrates potential for wide-ranging synergy and represents
a highly novel and attractive means of improving anti-merozoite
vaccine-induced nAb efficacy. Cooperativity between pairs of
mAbs targeting a single pathogen protein has been described
before, whereby two mAbs specific for the same protein display
synergistic neutralizing effects. For instance, cooperativity
involving non-neutralizing mAbs to Ebolavirus glycoprotein and
Neisseria meningitidis fHBP have been reported (Howell et al.,
2017; Beernink et al., 2008). However, to our knowledge, non-
neutralizing antibodies like R5.011 that potentiate multiple
nAbs against the same and other antigenic targets have not
been described for other pathogens. In addition to offering a
potential explanation for the surprisingly low GIA EC50 of human
PfRH5-specific pAb reported previously (Payne et al., 2017), this
potentiating phenomenon is an alluring explanation for the
synergy reported before between PfRH5 antibodies and those
binding other merozoite proteins such as PfRH4 (Williams
et al., 2012), PfCyRPA (Reddy et al., 2015), as well as PfMSRP5
and PfRAMA (Bustamante et al., 2017). In addition, if comple-
ment neutralization of merozoites acts in the timescale of normal
merozoite exposure, as has been argued before (Boyle et al.,
2015), extending this time with potentiating antibodies could
provide another avenue for synergy with complement.
Notably, we demonstrated there is still substantial room for
improvement through adding mAb R5.011 to vaccine-induced
human pAb samples, suggesting new avenues to maximize the
potency of next-generation PfRH5-based vaccines destinedCell 178, 216–228, June 27, 2019 225
for clinical development. Although relatively high concentrations
(around 200 mg/mL) of R5.011 are needed to leverage this effect
to its fullest, antigen-specific antibody titers of this magnitude
can be achieved in humans (Garc¸on et al., 2003), however,
eliciting them to a small portion of PfRH5may prove challenging.
Delivering potentiating antibody clones alongside a traditional
vaccine using vectored immunoprophylaxis (Balazs et al.,
2011) could be a more viable alternative. Furthermore, more
potent R5.011-like mAbs may be identified in larger sets of
anti-PfRH5 mAbs or generated by protein engineering, to
achievemaximal effect at lower antibody concentrations. Finally,
if one or a combination of R5.004, R5.011, or R5.016 (or closely
related mAbs) were used as a therapeutic, natural variation in
PfRH5 sequence is unlikely to affect their binding as the only mu-
tations in the vicinity of these contact sites are extremely rare or
known not to adversely affect binding.
Overall, the data presented here support the view that
vaccine-induced anti-PfRH5 pAb growth inhibition represents
a synthesis between the neutralizing effect of nAb and potentia-
tion from R5.011-like antibodies, balanced against antagonism
caused by competing antibodies. Immuno-focusing on key
epitope regionswill be critical for next-generation PfRH5 vaccine
design, and the agreement of GIA assay data with in vivo
protection in NHP (Douglas et al., 2015), as well as identification
of anti-PfRH5 mAb clones with in vivo efficacy against
P. falciparum in humanized mice and Aotus monkeys (Foquet
et al., 2018; Douglas et al., 2019), further underpins this strategy.
Antagonism also undoubtedly occurs, through competition be-
tween clones binding overlapping epitopes. Furthermore, one
can imagine antagonistic antibodies in which the Kon of the
antagonist is much higher than that of the nAb, leading to a
greater effect. The latter type of antibody clone will be detri-
mental to the overall neutralizing activity of anti-PfRH5 pAb,
and thus removal of these epitopes from PfRH5-based vaccine
immunogens can only be beneficial. Similarly, there is nothing
obvious to gain by inducing the antibodies that appear to have
no growth inhibitory or synergistic effects—40% of those
found in this study.
Our discovery of synergistic and functionally important
‘‘non-neutralizing’’ epitopes challenges the paradigm of struc-
tural vaccinology that traditionally sees the advancement of
epitopes against which overtly neutralizing antibodies are
directed. It is therefore important that future immunogen design
strategies for the development of PfRH5-based vaccines use the
structural insights obtained here to focus the human immune
response to generate both neutralizing and potentiating anti-
bodies. These data thus provide a strategy to design effective
PfRH5-based blood-stage malaria vaccines that provide func-
tional anti-merozoite immunity at lower overall concentrations
of PfRH5-specific human IgG.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human blood sample collection
Healthy, malaria-naive males and non-pregnant females aged 18-50 were invited to participate in the VAC057 study of the PfRH5-
based vaccine (Payne et al., 2017). VAC057 was a first-in-human, open-label, non-randomized, dose escalation Phase Ia clinical trial
evaluating the safety and immunogenicity of the viral vectored vaccines ChAd63 RH5 and MVA RH5 in a heterologous prime-boost
regime with an eight week interval. The study was conducted in the UK at the Centre for Clinical Vaccinology and Tropical Medicine
(CCVTM), University of Oxford, Oxford, and the NIHRWellcome Trust Clinical Research Facility (WTCRF) in Southampton. The study
received ethical approval from the Oxfordshire Research Ethics Committee A in the UK (REC reference 14/SC/0120). The study was
also reviewed and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA, reference 21584/0331/001-
0001). Volunteers signed written consent forms and consent was verified before each vaccination. The trial was registered on
Clinicaltrials.gov (NCT02181088) and was conducted according to the principles of the current revision of the Declaration of Helsinki
2008 and in full conformity with the ICH guidelines for Good Clinical Practice (GCP). The primary endpoint of the study was to assess
the safety of ChAd63 RH5 and MVA RH5, with a secondary endpoint to assess immunogenicity. Human blood samples were
collected into lithium heparin-treated vacutainer blood collection systems (Becton Dickinson). PBMC were isolated and used within
6 hours in fresh assays, otherwise excess cells were frozen in fetal calf serum (FCS) containing 10% dimethyl sulfoxide and stored in
liquid nitrogen. Plasma samples were stored at 80C. For serum preparation, untreated blood samples were stored at room tem-
perature and then the clotted blood was centrifuged for 5 min at 1000g. Serum was stored at 80C.
Experimental animal models
Sprague Dawley rat and female New Zealand White rabbit immunizations (PfRH5FL, PfRH5DNL and PfRipr) were carried out by
Genscript (Piscataway, NJ, USA). GenScript holds a valid and current AnimalWelfare Assurance in compliance with the Public Health
Service (PHS) Policy on humane Care and Use of Laboratory Animals as granted by the Office of Laboratory Animal Welfare (OLAW).
Female New ZealandWhite rabbit immunizations (PfCyRPA) were carried out by Cambridge Research Biochemicals (Billingham, UK)
in compliance with the UK Animals (Scientific Procedures) 1986 Act (ASPA). Female New Zealand White rabbit immunizations
(PfRH4, PfMSP1 and PfAMA1) were carried out by Agro-Bio (La Ferte´ Saint Aubin, France) according to the current French version
of the European Directive 2010/63/EU and following a protocol approved by their internal ethics committee. The study using liver-
humanized FRGN KOmice was carried out in accordance with the recommendations of the NIH Office of Laboratory Animal Welfare
standards (OLAW welfare assurance # A3640-01). The protocol was approved by the Center for Infectious Disease Research Insti-
tutional Animal Care and Use Committee (IACUC) under protocol SK-16.
Cell lines
Adherent HEK293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-Aldrich) supplemented with 2 mM
L-glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin, 0.1 mg/mL streptomycin and 10% ultra-low IgG fetal bovine serum
(FBS) (all from Thermo Fisher Scientific) in a static incubator at 37C, 8% CO2. Expi293F HEK cells were cultured in suspension in
Expi293 expression medium (Thermo Fisher Scientific) at 37C, 8% CO2, on an orbital shaker set at 125 RPM. Drosophila S2
were cultured in suspension in EX-CELL 420 medium (Sigma-Aldrich) supplemented with 100 U/mL penicillin, 0.1 mg/mL strepto-
mycin and 10% FBS at 25C.
METHOD DETAILS
Generation of monoclonal antibodies
Plasmablast isolation and sorting
Volunteers from a Phase Ia safety and immunogenicity clinical trial were bled seven days after the second immunization using MVA
(modified vaccinia virus Ankara) encoding PfRH5FL (Payne et al., 2017). Blood was collected from volunteers in heparinized tubes
and centrifuged in Leucosep tubes (Greiner Bio one) to separate the peripheral blood mononuclear cells (PBMC). The PBMC
were enriched for B cells using a human pan-B cell enrichment kit (StemCell Technologies, Inc.) and resuspended in DMEM before
staining with a CD19+, CD10–, CD21–, CD27+, CD20–, CD38+, IgG+ fluorophore-conjugated antibody panel. Plasmablasts were
single-cell sorted using aMoFlo cell sorter (Dako cytomation) into 96-well PCR plates containing 10 mL of 10 mM Tris HCl buffer con-
taining 40 U/mL of RNase inhibitor (Promega). The study received ethical approval from the Oxfordshire Research Ethics Committee
A in the UK (REC reference 14/SC/0120). The volunteers signed written consent forms and consent was verified before each
vaccination.
Antibody variable gene amplification
In each well of a 96-well plate containing a single antibody-secreting cell (ASC), a two-step RT-PCR was carried out with a first
reverse transcription (RT) step using a Sensiscript RT kit (QIAGEN) and degenerate primers 1-17 (modified from Tiller et al. [2008])
(see Table S4). Next, a first PCR (PCR1) was performed on 1 mL of the RT reaction product using the same set of primers used before
(1-17) which cover the diversity of all Vg, Vk and Vl sequences using Phusion HFmaster mix (New England Biolabs). Following this, a
second PCR (PCR2) was performed using primers 18-51 (Table S4), also using Phusion HF master mix, on 1 mL of the previouse4 Cell 178, 216–228.e1–e10, June 27, 2019
product diluted 1:100 to amplify inserts which contain plasmid-homologous extensions designed for circular polymerase extension
cloning (CPEC) (Quan and Tian, 2009).
Cloning
The AbVec-hIgG1/AbVec-hIgKappa/AbVec-hIgLambda expression plasmids were a kind gift from Patrick C. Wilson (University of
Chicago) (Wrammert et al., 2008). These plasmids were 50 digested using BshTI and at the 30 using SalI (AbVec-hIgG1), XhoI
(AbVec-hIgLambda) and Pfl23II (AbVec-hIgKappa) to yield linear products. CPEC assembly was done bymixing 100 ng of a 1:1molar
ratio of insert:plasmid in 20 mL containing 1x Phusion HF polymerase master mix and assembled using an 8-cycle CPEC protocol
(8 cycles: 98C 10 s, slow ramp anneal 70C/ 55C at 0.1C/s, 72C 35 s). Full nicked plasmids were subsequently transformed
into Zymo 5aMix & go competent Escherichia coli (Zymo Research) according to manufacturer’s instructions, streaked on LB agar
Petri dishes containing 100 mg/mL carbenicillin and grown at 37Covernight in a static incubator. Colonies were screened by PCR for
inserts of the correct size.
Screening
Exponential growth-phase adherent HEK293T cells were resuspended in DMEM (Sigma-Aldrich) supplemented with 2 mM L-gluta-
mine, 1 mM sodium pyruvate, 100 U/mL penicillin, 0.1 mg/mL streptomycin and 10% ultra-low IgG FBS (all from Thermo Fisher
Scientific) and seeded at 4 3 104 cells/well in 100 mL 24 h prior to transfection in Costar 96-well cell culture plates (Corning). On
the day of transfection, for each well, 50 mL of 60 mg/mL linear 25 kDa PEI (Alfa Aesar) was mixed with 200 ng of cognate
heavy- and light-chain coding plasmid in a volume of 50 mL and shaken at 20C for 30min. The DNA-PEI complexes were then added
to the HEK293T cells. The next day, an additional 50 mL of supplemented DMEM (as described above) was added to each well.
Supernatants were screened for PfRH5FL binding by indirect ELISA as described in the ELISA methods section.
Protein expression and purification
The recombinant PfRH5 sequence used in all experiments except for those involving BLI (Figures 1C, 3A, S3A, and S3B; Table S1)
was based on the 3D7 clone P. falciparum reference sequence and encoded amino acids E26-Q526. The sequence also encoded a
C-terminal four-amino acid purification tag (C-tag: EPEA) and four mutations to delete N-linked glycosylation sequons (T40A, T216A,
T286A and T299A) andwas named ‘‘PfRH5FL’’ (this recombinant protein is also known as ‘‘RH5.1’’) (Jin et al., 2018). This protein was
expressed as secreted protein by a stable monoclonal Drosophila S2 cell line (Hjerrild et al., 2016) and affinity purified using
CaptureSelect C-tag affinity matrix (Jin et al., 2017) (Thermo Fisher Scientific). A further size-exclusion chromatography (SEC)
polishing step was done on a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) to separate monomers from oligomers and
contaminants as well as to buffer-exchange the protein into 20 mM Tris, 150 mM NaCl, pH 7.5. A detailed description of the
production of PfRH5FL was described by Jin et al., 2018. The recombinant PfRH5 sequence (also named ‘‘PfRH5FL’’ for simplicity)
used in BLI experiments also encoded amino acids E26-Q526 of the 3D7 clone P. falciparum reference sequence, with only two
mutations to delete N-linked glycosylation (N38Q and N214Q). This sequence is identical to the vaccine sequence (Payne et al.,
2017) and was expressed with an additional C-terminal AviTag and Strep-II tag in tandem. This protein was expressed in Expi293F
HEK cells as a secreted, monobiotinylated protein as described previously by Bushell et al. (2008).
The recombinant PfRH5DNL sequence used was based on the 3D7 clone P. falciparum reference sequence and encoded amino
acids K140-K247 and N297-Q526 with two mutations to delete N-linked glycosylation sequons (T216A and T299A) and with the
addition of a C-terminal C-tag. PfRH5DNLwas expressed as secreted protein from stably transfected polyclonalDrosophila S2 cells.
Its purification is detailed in the X-ray crystallography experimental procedures section.
The PfRipr expression construct used for rabbit vaccination to yield IgG used in Figures 5E and S5F comprised amino acids
M1-N1086 with eight mutations introduced to ablate N-linked glycosylation (N103Q, N144Q, N228Q, N334Q, N480Q, N498Q,
N506Q, N526Q, N646Q, N647Q, N964Q and N1021Q) followed by a C-terminal C-tag. PfRipr was purified by C-tag affinity chroma-
tography followed by SEC as detailed above for PfRH5. The expression construct used for monomeric PfCyRPA production in Fig-
ure 3C and rat vaccination in Figure S5F was based on the 3D7 clone P. falciparum sequence and comprised amino acids D29-E362
with three mutations introduced to ablate N-linked glycosylation (S147A, T324A and T340A) and also included a C-terminal GGGS
linker followed by a 4-amino acid C-tag (EPEA). The PfCyRPA immunogen sequence used for rabbit vaccination in Figure 5E was
identical to that described above with the C-tag replaced by a C-terminal CD4 tag comprising rat domains 3 and 4 (CD4d3+4) tag
followed by a hexahistidine (His6) tag. The protein was expressed as secreted protein from Expi293F HEK cells and purified by
C-tag affinity chromatography followed by SEC on a HiLoad 16/60 Superdex 200 pg column (GE Healthcare). Basigin protein
comprised of immunoglobulin domains 1 and 2 of the short isoform (residues A22-H205) and was expressed from E. coli and purified
by Ni2+-affinity and size exclusion chromatography. Further details can be found in Wright et al., 2014. PfP113Nt, encoding amino
acids Y23-K219 of PfP113 (3D7) and PfRH5Nt encoding amino acids F25-K140 of PfRH5 (3D7), were expressed encoding C-terminal
tags comprising CD4d3+4, a biotin acceptor peptide and a His6 tag in tandem. For further details see Galaway et al. (2017).
Recombinant monoclonal antibodies were transiently expressed in Expi293F HEK cells. Cognate heavy and light chain-coding
plasmids were co-transfected at a 1:1 ratio. Supernatants were harvested by centrifuging the culture at 2500 xg for 15 min and
filtering the supernatant with a 0.22 mm vacuum filter. All mAbs were purified using a 5 mL Protein G HP column (GE Healthcare)
on an A¨KTA start FPLC system or an A¨KTA Pure FPLC system (both GE Healthcare). Equilibration and wash steps were performed
with Dulbecco’s PBS and mAbs were eluted in 0.1 M glycine pH 2.7. The eluates were pH equilibrated to 7.4 using 1.0 M Tris HCl pH
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(Millipore) with a molecular weight cut-off of 30 kDa. IgG from serum in Figures 3E, 3F, 3H, 5C, 5E, S5B, and S5F was purified on drip
columns packed with Pierce Protein G agarose resin (Thermo Fisher Scientific). Pierce protein G IgG binding buffer (Thermo Fisher
Scientific) was used to dilute the serum 1:1 before loading as well as for equilibration and wash steps. Bound IgG was subsequently
eluted, neutralized and concentrated as above. Bispecific DVD-Ig 1611 was constructed by cloning R5.016 variable regions up-
stream (50) of R5.011 variable regions, separated by ASTKGPSVFPLAP and TVAAPSVFIFPP linkers for the heavy and light chains,
respectively. 1611 DVD-Ig expression and purification was conducted as described above for monospecific mAbs.
X-Ray crystallography
Complex preparation
PfRH5DNLwas purified fromDrosophila S2 culture supernatant using C-tag affinity chromatography and glycosylated contaminants
were removed by a subsequent lectin chromatography stepwith a HiTrap ConA 4B column (GEHealthcare). Disordered regions were
trimmed by an overnight incubation at 20Cwith endoproteinase gluC (New England Biolabs) at a final concentration of 1 mg/mL. Fab
fragments were generated by papain digestion using a Pierce Fab Preparation Kit (Thermo Fisher Scientific) following the manufac-
turer’s recommendations. Complexes were prepared by mixing each Fab fragment with PfRH5DNL at a 1:1 molar ratio and were
methylated with 1 M ABC (Borane dimethylamine complex) and 1 M formaldehyde (both Sigma-Aldrich) (Walter et al., 2006). The
methylated complexes were subjected to SEC on a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) at 4C in 20 mM Tris
pH 7.4, 150 mM NaCl. The complex-containing fractions were pooled and concentrated using an Amicon ultra centrifugal concen-
trator (Millipore) with a molecular weight cut-off of 30 kDa.
Crystallization, data collection and processing
Crystallization was achieved using vapor diffusion in sitting drops. Crystals were obtained for the Fab fragments of mAbs R5.004,
R5.011 and R5.016 alone, as well as for complexes consisting of PfRH5DNL:R5.004:R5.016 and PfRH5DNL:R5.011:R5.016. In
each case, a TTP Labtech Mosquito LCP robot was employed to mix 100 nL of each protein complex at a concentration of
10 mg/mL with 100 nL of well solutions from commercially available crystal screens.
Crystals of R5.004 Fab fragments were obtained in the JCSG-plus crystallization screen (Molecular Dimensions) and were opti-
mized with a final well solution of 0.2 M lithium sulfate, 0.1 M NaAc pH 4.5, 30% PEG 8000 and 0.06% hexamminecobalt(III) chloride,
12 mMMESmonohydrate, 12 mMPIPES, 4 mMHEPES chloride (Silver bullet additive D3, Hampton Research). They were cryo-pro-
tected by transfer into well solution supplemented with 25% glycerol, then cryo-cooled by plunging into liquid nitrogen. Data were
collected on beamline I-03 at Diamond Light Source (Harwell, UK), leading to a complete dataset at a resolution of 1.7 A˚.
Crystals of R5.016 Fab fragments were obtained in the JCSG-plus crystallization screen (Molecular Dimensions), with a final well
solution of 0.2M lithium sulfate, 0.1MNaAc pH 4.5, 50%PEG 400. Crystals were cryo-cooled directly in the well solution by plunging
into liquid nitrogen. Data were collected on beamline I04-1 at Diamond Light Source (Harwell, UK), leading to a complete dataset at a
resolution of 2.1 A˚.
Crystals of R5.011 Fab fragments were obtained in the NeXtal JCSG-IV crystallization screen (QIAGEN), with a final well solution of
0.16M ZnAc, 0.108MNa cacodylate pH 6.5, 14.4%PEG 8000, 20%glycerol. They were cryo-protected by transfer into well solution
supplemented with 25% glycerol, then cryo-cooled by plunging into liquid nitrogen. Data were collected on beamline PROXIMA-1 at
SOLEIL (Saint-Aubin, France), leading to a complete dataset at a resolution of 2.3 A˚.
Crystals of the PfRH5DNL:R5.004:R5.016 complex were obtained in the JCSG-plus crystallization screen (Molecular Dimensions),
with a final well solution of 0.15 M DL malic acid, 20% PEG 3350. They were cryo-protected by transfer into well solution supple-
mented with 25% glycerol, then cryo-cooled by plunging into liquid nitrogen. Data were collected on beamline I04 at Diamond Light
Source (Harwell, UK), leading to a complete dataset at a resolution of 4.0 A˚.
Crystals of the PfRH5DNL:R5.011:R5.016 complex were obtained in the Morpheus crystallization screen (Molecular Dimensions),
with a final well solution of 10% PEG 20000, 20% PEG 550MME, 0.02 M amino acids, 0.1 M MES/imidazole pH 6.5. Crystals were
cryo-cooled directly in the well solution by plunging into liquid nitrogen. Data were collected on beamline ID23 at the European
Synchrotron Radiation Facility (Grenoble, France), leading to a complete dataset at a resolution of 3.6 E.
In each case, data reduction was performed using XDS (Kabsch, 2010). Molecular replacement solutions were found for each in-
dividual Fab fragment, using Phaser (McCoy et al., 2007) with the most closely related Fab fragment structure in the PDB, split into
their constant and variable domains, as search models (4KQ3 for R5.004, 4HK0 for R5.011 and 5K9O for R5.016). This led to a cycle
of model building and refinement using COOT (Emsley et al., 2010) and BUSTER (Bricogne et al., 2011). For R5.004, this resulted in a
complete model for the Fab fragment. For R5.011, this resulted in a complete model for the Fab fragment, with the exception of res-
idues 143-148 in the heavy chain, which were disordered in the electron density map. For R5.016, this resulted in a complete model
for the Fab fragment, with the exception of residues 103-108 in the heavy chain and 1-7, 25-29 and 55-58 in the light chain, all of which
were disordered in the electron density map.
The structure of the PfRH5DNL:R5.011:R5.016 complex was obtained to 3.6 A˚ resolution using Phaser with the structure of
PfRH5DNL (PDB code: 4U0R) and those of Fab fragments obtained above, split into their constant and variable domains, as search
models. All domains were well resolved, although significant changes in conformation were observed in CDR H3 of both R5.011 and
R5.016, as a result of PfRH5DNL binding. COOT, BUSTER and PHENIX (Afonine et al., 2012) were used for refinement, including
application of restraints that derived from the higher resolution structures of PfRH5DNL and the shared regions of the Fab fragments.
This allowed the production of a final model in which all of the Fab fragment domains, and all of the CDR loops, were clearly resolved.e6 Cell 178, 216–228.e1–e10, June 27, 2019
The structure of the PfRH5DNL:R5.004:R5.016 complex was obtained at 4 A˚ resolution, using Phaser. The structure of PfRH5DNL
bound to the variable domain of R5.016, obtained from the structure of the PfRH5DNL:R5.011:R5.016 complex, and the structure of
the variable domain of R5.004 obtained above, were used as search models in Phaser. No significant changes were observed in the
CDR loops of the Fab fragment of R5.004. Placement of the constant domains of R5.016 and R5.004 was challenging, due to anisot-
ropy resulting from disorder within the crystal. These domains were therefore placed using real space docking after refinement in
BUSTER of a structure consisting of PfRH5DNL and the variable domains of R5.004 and R5.016. This gave unambiguous electron
density for the regions of the constant domains which lie close to the contact with the variable domains, but, after refinement, electron
density is still absent for the PfRH5DNL-distal parts of the constant domains. Refinement in COOT, BUSTER and PHENIX allowed the
production of a final model in which the Fab fragment domains, and all of the CDR loops, were clearly resolved.
Humanized mouse passive transfer
P. falciparum sporozoite production and mouse infection
The luciferase expressing strain P. falciparum NF54HT-GFP-luc was maintained in RPMI 1640 supplemented with 25 mM HEPES,
2 mM L-glutamine, 50 mM hypoxanthine, 10% human serum and sub-cultured in 5% human group O RhD positive human RBC.
Briefly, asexual cultures were inoculated at 1% parasitemia with no further sub-culturing and daily media changes to induce game-
tocytogenesis. Mature gametocytes were fed to 4-day old Anopheles stephensi mosquitoes to initiate infection. Mosquitoes were
incubated at 27C and 75% humidity for 14 d and given 8% dextrose + PABA to foster parasite growth. Liver humanized FRGN
KOmice were purchased from Yecuris Corp. and showed human hepatocyte repopulation levels above 70% determined by human
serum albumin levels. Liver humanized mice were cycled on NTBC once a month for 3 d at 8 mg/mL in the drinking water to maintain
health. Animals did not receive NTBC three weeks prior to and during the infection study. For mosquito bite infection, 3-5 liver hu-
manized FRGN KO mice were anesthetised and placed on top of a mosquito cage containing 150-250 infected mosquitoes
for 20 min.
P. falciparum liver-to-blood stage transition
On the day of challenge, liver humanized FRGN KOmice were injected both in the retro-orbital plexus and the peritoneal cavity with
50 mL clodronate-containing liposomes (Clophosome-A, FormuMax Scientific), 100 mg/kg cyclophosphamide (Sigma-Aldrich).
Five days after challenge, the animals were bled a volume of approximately 200 mL, and 500 mL hRBCwas injected in the retro-orbital
plexus (70% O+ human erythrocytes in RPMI 1640 supplemented with 25 mM HEPES, 2 mM L-glutamine, 50 mM hypoxanthine and
10%human serum). The next day, mice were bled 200 mL and received an intraperitoneal injection of 700 mL hRBC.mAb transfer was
done on day 6 to precede the establishment of blood-stage infection. Dosage was 15 mg total rabbit IgG per mouse formulated in
PBS and delivered intravenously. The clodronate liposome and cyclophosphamide injections were repeated on days 5, 9, 11, 13.
Human RBC were injected daily in a volume of 300-700 mL to keep the percentage of hRBC stable around 50%–60%. If the percent-
age reached more than 70%, the mice were not injected with hRBC to limit morbidity. On days 9, 11 and 13 each mouse was bled
from the retro-orbital plexus to sample antibody levels.
Quantification of parasite burden
Luciferase activity wasmeasured in themice using the IVIS Lumina II animal imager (Perkin Elmer). The abdomen of micewas shaved
to enhance detection. Mice were injected intraperitoneally with 100 mL of luciferase substrate RediJect D-Luciferin (Perkin Elmer) to
quantitate specific enzymatic activity. Animals were anesthetized and imagedwithin 5min of substrate injection. Signal was acquired
for 5min using a field of view of 10 cm andmedium binning factor. Living Image 3.0 software was used tomeasure total flux (photons/
second) of a region of interest, which was placed around each mouse. A comprehensive description of the mouse model was pub-
lished by Foquet et al., 2018.
PfCyRPA/PfP113/BSG SPR blocking assays
Data were collected on a Biacore X100 (GEHealthcare). All data usedwere reference subtracted from a non-immobilized flow cell (Fc
2-1). Binding values were measured manually in the Biacore X100 control software.
PfRH5-basigin binding
Experiments were performed at 25C in SPR running buffer (PBS + 0.005% Polysorbate-20, GE Healthcare). Approximately 670 RU
of basigin was amine-coupled to a CM5 chip (GEHealthcare) on flow cell 2 (Fc 2) using standard NHS/EDC chemistry. PfRH5FL-mAb
complexes weremade bymixing PfRH5FL andmAb to a final concentration of 0.5 mMPfRH5FL and 1 mMmAb in SPR running buffer.
Complexes were injected over Fc 1 and Fc 2 at a flow rate of 10 mL/min for 30 s and the surface was regenerated with 10 mM glycine
pH 1.5 for at a flow rate of 10 mL/min for 60 s. Between experiments, one injection of 0.5 mM PfRH5FL was made to assess basigin
degradation caused by regeneration.
PfRH5-PfCyRPA binding
Experiments were performed at 25C in SPR running buffer (PBS + 0.005% Polysorbate-20, GE Healthcare) using a sensor chip pro-
tein A (GEHealthcare). mAbwas injected at a concentration of 20 nM at a flow rate of 5 mL/min for 35 s over Fc 2 on a protein A coated
chip (GE Healthcare). Next, PfRH5FL was injected over Fc 1 and Fc 2 at a concentration of 50 nM at a flow rate of 10 mL/min for 120 s
before injecting PfCyRPA at a concentration of 1 mM for 120 s, also at a flow rate of 10 mL/min. The chip surface was regenerated with
10 mM glycine pH 1.5 for at a flow rate of 10 mL/min for 60 s.Cell 178, 216–228.e1–e10, June 27, 2019 e7
PfRH5-PfP113 binding
Experiments were performed at 37C in SPR running buffer (PBS + 0.005%Polysorbate-20, GE Healthcare) using a Sensor chip CAP
(GE Healthcare). The whole experiment was run at a flow rate of 5 mL/min. Approximately 1500 RU of CAP reagent (GE Healthcare)
was captured on Fc 1 and Fc 2. On Fc 1, approximately 500 RU of a biotinylated control CD4d3+4-tagged protein was immobilized.
On Fc 2, each experiment consisted of capturing 1500 RU of CAP reagent in an 80 s injection followed by approximately 1800 RU of
PfP113Nt in an 80 s injection at a concentration of 20 mg/mL. After this, PfRH5FL-mAb complex (both at 1 mM) was flowed over Fc 1
and Fc 2. Flow cell 2 was regenerated between experiments in a 110 s injection of 6 M guanidine + 250 mM NaOH, as per the man-
ufacturer’s instructions.
Bio-Layer Interferometry
All BLI was carried out on an OctetRED384 (Forte´Bio) using streptavidin-coated biosensors (Forte´Bio) to immobilize PfRH5FL enzy-
matically monobiotinylated on a C-terminal AviTag. Assays were carried out in 96-well format in black plates (Greiner). For assaying
mAb binding to PfRH5FL variants (Figure 1C), the experiment followed a four-step sequential assay: Baseline (PBS, 30 s); Protein
immobilization (neat supernatant, 180 s); Wash (PBS, 60 s); and mAb binding (150 nM mAb, 120 s). Graphed data show the fold-
change in binding of eachmAb to the 3D7 PfRH5FL reference protein relative to the binding of eachmAb to eachmutant protein after
correction for PfRH5FL immobilization level on each biosensor. The fold-change values which were inferior to 1 were plotted as their
inverse to avoid skewing in their data representation compared to fold-change values greater than 1. For epitope binning studies in
Figures 3A and S3A and Table S1 the experiment followed a six-step sequential assay: Baseline (PBS, 30 s); Protein immobilization
(neat supernatant, 120 s); Wash (PBS, 60 s); mAb1 binding (300 nM mAb1, 120 s); Wash (PBS, 60 s); mAb2 binding (150 nM mAb2,
120 s). ‘‘Relative binding’’ shown in Table S1 shows the ratio (SignalmAb2 with mAb1 bound)/(SignalmAb2 with no mAb1) where
‘‘SignalmAb2’’ was normalized for the amount of PfRH5FL bound to the biosensor such that ‘‘SignalmAb2’’ = the raw signal in
‘‘mAb2 binding’’ divided by the raw signal in the ‘‘Protein immobilization’’ phase. The resulting ‘‘binding profile’’ for any given
mAb corresponds to the column of ‘‘relative binding values’’ under that mAb in the ‘‘relative binding’’ table. To establish the epitope
bins, binding profiles between each mAb pair was correlated using a person product-moment correlation coefficient, the values of
which are shown in the ‘‘binding profile correlation’’ table in Table S1. mAb pairs whose binding profile correlation was > 0.7 were
grouped into the same epitope bin.
ELISA
Qualitative mAb binding ELISAs such as those used in Figures 1D, 3D, and S3F were carried out by coating PfRH5FL, PfRH5DNL or
PfRH5Nt on Maxisorp flat-bottom 96-well ELISA plates (Nunc) at 2 mg/mL in 50 mL at 4C overnight. In Figure 1D, PfRH5FL was heat-
treated by incubation at 90C for 10 min. Plates were then washed twice with PBS-Tween 20 and blocked with 200 mL of Blocker
Casein (Thermo Fisher Scientific) for 1 h. Next, wells were incubated with 1000 ng/mL of mAb for approximately 45 min at 20C
then washed 4 times with PBS-Tween 20 before the addition of 50 mL of goat anti-human gamma-chain alkaline phosphatase-
conjugated secondary antibody (goat anti-mouse IgG alkaline phosphatase-conjugated secondary antibody for QA1) (both
Sigma-Aldrich) for 45min at 20C.Wells were thenwashed 6 timeswith PBS-Tween 20 and developedwith 100 mL of pNPP substrate
at 1 mg/mL (Sigma-Aldrich) and read at 405 nm.
Peptide ELISAs in Figure S3E were carried out with a set of sixty-two custom-synthesized biotinylated 20-mer peptides of PfRH5
overlapping by 12 amino acids (Mimotopes). The list of peptide sequences was described previously by Payne et al., 2017. Briefly,
the peptides were designed to be oriented and tethered by their N-terminal biotinylated linker peptide (biotin-SGSG) with the
exception the first peptide which contained the biotinylated linker at its C terminus to preserve potential binding activity to
the most N-terminal residues. These peptides were coated to the bottom wells of a streptavidin-coated 96-well plate in 50 mL.
The next day wells were blocked with 200 mL of Blocker Casein (Thermo Fisher Scientific) and washed five times with PBS-Tween
20. Bound mAbs were detected using an anti-human gamma-chain-specific alkaline phosphatase-conjugated secondary antibody
(Sigma-Aldrich) or the mouse equivalent for QA1 in 50 mL for 30 min at a dilution of 1:1000 in PBS and washed six times with
PBS-Tween 20 before being developed with 100 mL of pNPP alkaline phosphatase substrate for 20min and read at 405 nm. To deter-
mine total PfRH5FL-specific IgG as in Figures 3F and 3I, standardized methodology was used as described previously (Sheehy et al.,
2011; Payne et al., 2017). Responses measured in AU are reported in mg/mL following generation of a conversion factor by calibra-
tion-free concentration analysis (CFCA). For the calculation of the conversion factor, see Williams et al. (2012).
Animal immunization
In Figures 3F–3H and S5B using PfRH5-reactive IgG, two groups of six outbred New Zealand White rabbits were immunized three
times three weeks apart and terminally exsanguinated two weeks following the final vaccination. Vaccines were formulated as equi-
molar doses (29 mg of PfRH5FL or 20 mg of PfRH5DNL per dose) in 50% v/v AddaVax adjuvant (InvivoGen), a squalene-based
oil-in-water nano-emulsion and administered by intramuscular (i.m.) route by GenScript. In Figures 5E and S5F, anti-PfAMA1,
anti-PfMSP1 and anti-PfRH4 antisera were generated in rabbits as previously reported (Douglas et al., 2011; Williams et al.,
2012). For PfCyRPA, rabbit immunizations to generate the IgG used in Figure 5E were carried out by Cambridge Research Biochem-
icals. New Zealand white female rabbits (n = 2) were immunized i.m. on day 0 with 100 mg of PfCyRPA protein formulated in AddaVax
adjuvant (InvivoGen) followed by two i.m. booster immunizations on days 28 and 56. Serum was collected 1 week after the finale8 Cell 178, 216–228.e1–e10, June 27, 2019
immunization on day 63. To generate the PfCyRPA-reactive IgG used in Figure S5F, a single Sprague Dawley rat was immunized
three times on day 0, day 28, day 56 and terminally exsanguinated two weeks following the final vaccination. Vaccines were formu-
lated as 50 mg doses in complete Freund’s adjuvant for the initial vaccination and incomplete Freund’s adjuvant for the following two,
and administered i.m by GenScript. To generate the PfRipr-reactive IgG used in Figures 5E and S5F, a single New Zealand White
rabbit was immunized four times on day 0, day 14, day 28, day 42 and terminally exsanguinated two weeks following the final vacci-
nation. Vaccines were formulated as 20 mg doses in complete Freund’s adjuvant for the initial vaccination and incomplete Freund’s
adjuvant for the following three, and administered i.m by GenScript.
Affinity determination by SPR
Data were collected on a Biacore X100 (GE Healthcare). Experiments were performed at 25C in Dulbecco’s PBS + 0.005%
Polysorbate-20 (GE Healthcare). In Figure 1B and Figure S1B, a sensor chip protein A (GE Healthcare) was used to capture
50-100 RU of purified mAb diluted in SPR running buffer at a flow rate of 5 mL/min on flow cell 2. Next, an appropriate range (typically
20 nM-0.625 nM) of six 2-fold dilutions with one replicate of PfRH5FL was injected for 90 s at 60 mL/min and dissociation was
measured for 1600 s (7200 s when necessary). The PfRH5FL analyte was > 95% pure as assessed by SDS-PAGE. Specific binding
of the PfRH5FL protein to mAb was obtained by reference-subtracting the response of a blank surface from that of the mAb-coated
surface. The sensor surface was regenerated with a 60 s pulse of 10 mM glycine-HCl pH 1.5 (GE Healthcare). In Figure S6E, sensor
chips CM5 (GE Healthcare) were amine-coupled with approximately 90 RU of R5.004 or R5.016 antibody on flow cell 2. Five two-fold
dilutions of PfRH5FL or PfRH5FL-R5.011 Fab fragment complex (made by co-incubating PfRH5FL with a 3-fold molar excess of
R5.011 Fab fragment for 30 min at room temperature; all PfRH5FL was bound by R5.011 Fab fragment as assessed by SEC)
were injected for 90 s at 60 mL/min at concentrations ranging from 10 nM to 0.625 nM and dissociation was measured for 800 s.
The R5.004 sensor chip surface was regenerated with a 30 s pulse of 10 mM glycine-HCl pH 3.0 (GE Healthcare) whereas the
R5.016 sensor chip surface was regenerated with a 30 s pulse of 10 mM glycine-HCl pH 1.5. Sensorgrams were fitted to a global
Langmuir 1:1 interaction model, allowing determination of the kinetic association and dissociation rate constants using Biacore
X100 evaluation software.
AVEXIS blocking assay
All AVEXIS assays were conducted at the Wellcome Trust Sanger Institute, Cambridge, UK (Bushell et al., 2008). Biotinylated mono-
meric bait protein was captured on streptavidin-coated flat-bottomed 96-well microtiter plates in 50 mL volumes for 1 h at 20C.
Plates were then washed 3 times with PBS and incubated with 50 mL of human PfRH5-specific mAb for 1 h at 20C. The
plates were washed 3 more times in PBS before the addition of 50 mL of pentameric b-lactamase-tagged prey proteins for a further
1 h at 20C. All wells were subsequently washed twice with PBS-Tween 20 and then twice with PBS before the addition of 150 mL/well
of the b-lactamase substrate nitrocefin. Absorbance readings were made at 485 nm. The protein constructs were all full-length
ectodomains with threonine to alanine mutations to remove N-linked glycosylation sequons (except for basigin) as previously re-
ported (Crosnier et al., 2011; Galaway et al., 2017): PfRH5 amino acids F25-Q526; PfCyRPA amino acids D29–E362; PfP113 amino
acids Y23-K942; and basigin isoform 2 amino acids M1-A23 followed by G140-L322. All bait and prey proteins were expressed as
fusion proteins N-terminal of a CD4d3+4 tag, a biotin acceptor peptide and a His6 tag. Prey proteins were expressed with a C-ter-
minal with a collagen oligomeric matrix protein (COMP) peptide to promote pentamerization and a b-lactamase enzyme for
quantification purposes.
Assay of GIA
All mAb GIA assays in Figures 2A–2C and 3E were performed at the GIA Reference Center, NIAID, NIH. Test mAbs were buffer
exchanged against RPMI 1640 (KD Medical) and concentrated to 6 mg/mL. The one-cycle GIA was performed at indicated concen-
trations of mAbs in duplicate wells and a biochemical measurement using a P. falciparum lactate dehydrogenase assay was used to
quantify parasitemia which has been described previously (Malkin et al., 2005). GIA assays performed with rabbit and rat polyclonal
antibody and mAb combinations in Figures 3F, 5, and S5 were performed at the Jenner Institute, University of Oxford using identical
protocols and procedures to those at the NIAID but in triplicate wells. Polyclonal IgG resulting from animal immunization were pre-
incubated with human group O RhD-positive RBC to eliminate spurious GIA results caused by hemagglutination.
Live-cell microscopy
Highly synchronous 3D7 parasite cultures at 4% hematocrit were diluted to 0.16% in warmed RPMI media and 0.2 mL of this was
added to each well of a Lab-Tek 8-well Chambered Coverglass (Thermo Fisher Scientific). IgGs were added at concentrations indi-
cated for each figure and the chamberwas immediately placed on into a preheated (37C) incubator stage of a Zeiss AxioObserver Z1
fluorescence microscope supplied with humidified gas (94% N2, 1% O2, and 5% CO2). Late stage schizonts that appeared ready to
rupture (Crick et al., 2013) were imaged with a Zeiss LCI Plan-NEOFLUAR 63x/1.3 DIC 1 mm Korr objective at 4 frames per second
with an AxioCam MRm camera. The schizonts were imaged for 20 minutes and if they did not rupture, a new schizont in a new well
was selected. The image files were cropped, time stamped and then converted to AVI video format in Zen microscopy software
(Zeiss). The behavior of invading merozoites was manually viewed in FIJI and the invasion statistics were analyzed and graphed
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Dot blot
Briefly, 1.5 mL of anti-PfRH5mAb, a human anti-Zaire EbolavirusGP IgG1mAb (a-EBOV) (Rijal et al., 2019), recombinant PfRH5FL (all
at 1 mg/mL) and PBS were spotted onto 0.2 mm nitrocellulose membrane and air-dried for 10 min. Afterward, the membrane was
blocked in 3% BSA + 3% skimmed milk in PBS for 1 h and washed in PBS. It was then immersed in P. falciparum 3D7 culture
supernatant for 1 h and washed again in PBS. Bound PfRH5FL was detected by incubating the membrane in PfRH5FL-immunized
rabbit serum diluted 2000-fold in PBS followed by an alkaline phosphatase-conjugated anti-rabbit IgG mAb (clone RG-96, Sigma-
Aldrich) also diluted 1:2000, separated by two wash steps in PBS. After a final series of five PBS washes, the dot blot was developed
with Sigmafast BCIP/NBT alkaline phosphatase substrate at 1 mg/mL (Sigma-Aldrich).
Hydrogen-deuterium exchange mass spectrometry
HDX-MS was performed using a Waters HDX platform composed of a liquid handling robotic setup (LEAP technologies) for sample
preparation and a nano-Acquity UPLC coupled to a Synapt G2-Si (Waters) mass spectrometer. Samples were prepared by 11-fold
dilutions from 7 mMof apo PfRH5FL or PfRH5FL-mAb complex in deuterated or non-deuterated 20mMHEPES, 150mMNaCl pH 7.4
buffer. The pH of the sample was brought down to 2.3 by adding 50% vol/vol 150 mMHCl. Non-deuterated and deuterated samples
were loaded by the robot. The apo PfRH5FL protein or PfRH5FL-mAb complex was digested in-line using a pepsin-immobilized col-
umn at 20C. The peptides generated from pepsin digestion were trapped on amicro peptide trap for 2 min for the removal of salts at
a flow rate of 200 mL/min and then separated using a C18 column with a linear gradient of 5%–80% acetonitrile (CH3CN) and water
both supplemented with 0.1% formic acid for 12min at flow rate of 40 mL/min. The liquid chromatography temperature was set at 0C
to reduce back-exchange. Sequence coverage and deuterium uptake were analyzed by using ProteinLynx Global Server (Waters)
and DynamX (Waters) programmes, respectively. Peptide mapping was obtained by using nondeuterated samples in triplicates
and only unique peptides present in all three data files were selected for deuterium uptake data analysis. Leucine enkephalin at a
continuous flow rate of 5 mL/min was sprayed as a lock mass for mass correction. Apo PfRH5FL protein digests provided a list of
2056 peptides, after applying several selection filters andmanual inspection only 127 peptideswere selected for analysis. These pep-
tides provided > 93% sequence coverage with many overlapping peptides. The samples were labeled for 20 s, 10 min and 2 h. All
HDX-MS experiments were performed in duplicate.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed using GraphPad Prism versions 5.04, 7.0.5 and 8.0.1 for Windows (GraphPad Software Inc.). In Figures 2B, 2C,
and 3F, a four-parameter sigmoidal dose-response curve was fitted to the relationship between Log10(antibody concentration) and
percentage GIA for each dataset and used to interpolate EC50 values. In Figure S2, the nonparametric Spearman’s rank correlation
coefficient (r) was used to assess a correlation between the variables Kon/Koff/KD and GIA EC30. In Figures 7A, 7B, and S7B, a
nonparametric Kolmogorov-Smirnov test was used to compare the cumulative frequency distribution of two groups. In all statistical
tests, reported P-values are two-tailed with p > 0.05 not considered significant.
DATA AND CODE AVAILABILITY
The crystal structures of unliganded R5.004, R5.011 and R5.016 Fab fragments have been deposited in the Protein Data Bank (PDB)
under ID codes 6RCO, 6RCQ and 6RCS, respectively. The crystal structure of R5.004 and R5.016 Fab fragments bound to PfRH5 as
well as that of R5.011 and R5.016 Fab fragments bound to PfRH5 can be accessed under PDB ID codes 6RCU and 6RCV,
respectively.e10 Cell 178, 216–228.e1–e10, June 27, 2019
Supplemental Figures
R5.006R5.001 R5.002 R5.003 R5.004
R5.007 R5.008 R5.009 R5.010 R5.011
R5.013 R5.014 R5.015 R5.016 R5.017
R5.018 R5.019 c2AC7 c4BA7 c9AD4
QA1 PfRH5FLPBSα-EBOV
B
C
mAb Kon (M-1s-1) Koff (s-1) KD (M)
R5.001 1.02E+06 1.65E-03 1.62E-09
R5.002 3.86E+05 4.91E-03 1.27E-08
R5.003 1.70E+06 1.86E-03 1.09E-09
R5.004 1.71E+06 1.09E-03 6.36E-10
R5.006 6.77E+05 2.34E-04 3.46E-10
R5.007 3.78E+05 3.26E-04 8.63E-10
R5.008 7.22E+05 6.39E-04 8.86E-10
R5.009 5.12E+05 2.72E-04 5.31E-10
R5.010 7.83E+05 3.63E-04 4.63E-10
R5.011 1.61E+06 1.67E-05 1.03E-11
R5.013 7.73E+05 6.02E-05 7.79E-11
R5.014 3.15E+06 <2.91E-06 <9.21E-13
R5.015 6.29E+05 4.23E-05 6.73E-11
R5.016 1.14E+06 4.88E-04 4.28E-10
R5.017 1.44E+06 2.91E-04 2.01E-10
R5.018 4.25E+05 6.71E-06 1.58E-11
R5.019 3.07E+06 4.72E-04 1.54E-10
c2AC7 5.16E+06 1.62E-04 3.14E-11
c4BA7 5.89E+05 2.55E-05 4.33E-11
c9AD4 3.63E+06 5.04E-04 1.39E-10
QA1 2.95E+05 7.27E-04 2.46E-09
A VAC057 Volunteer # Trial Group Time-point ChAd63 PfRH5FL Prime Dose (vp) MVA PfRH5FL Boost Dose (pfu)
2207 2C 5 x 1010 2 x 108
Day 63             
(7 days post-boost)
Day 63             
(7 days post-boost)
Day 63             
(7 days post-boost)
1017 2C 5 x 1010 2 x 108
1019 2B 5 x 1010 1 x 108
Figure S1. Clinical Trial (VAC057) Volunteer Information and Additional PfRH5 mAb Binding Data, Related to Figure 1
(A) Vaccination details of the three volunteers fromwhich anti-PfRH5FLmAbs were isolated. (B) List of anti-PfRH5mAb binding properties. Association-rate (Kon),
dissociation-rate (Koff) and affinity (KD) are shown. (C) Dot blot showing anti-PfRH5 mAbs binding to parasite-derived PfRH5. PBS, PfRH5FL and a recombinant
anti-Ebolavirus IgG1 mAb (a-EBOV) were used as controls.
Figure S2. Correlation between nAb Kinetic Binding Parameters and GIA, Related to Figures 2 and S1B
The binding parameters of nAbs (Kon, Koff and KD) were correlated with growth inhibition using the GIA EC30 as a measure of potency. Only GIA-high nAbs were
included in this analysis because of their overt ability to bind merozoite-bound PfRH5, as evidenced by their growth inhibitory properties. EC30 values were
calculated from data shown in Figure 2B. Reported P-values are two-tailed and considered significant if P <0.05.
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Figure S3. Further Investigations into Anti-PfRH5 mAb Binding Activity, Related to Figure 3 and Table S1
(A) Example graph of raw BLI data used to generate the epitope bins shown in Figure 3A. (B) Table of epitope bin exceptions. ‘‘Competing mAbs from separate
epitope bins’’ are mAb pairs in which mAb1 was able to reduce mAb2 binding byR 95% on a one-to-one basis but whose binding profile correlation coefficient
was too low to reach the 0.7 threshold. ‘‘Incompletely competing mAbs form the same epitope bin’’ are mAb pairs in which mAb1 was not able to reduce mAb2
binding byR 95% on a one-to-one basis but whose binding profile correlation coefficient was above the 0.7 threshold. (C) AVEXIS assays to determine mAb
inhibition of PfRH5FL binding to associated proteins basigin, PfCyRPA and PfP113. In these plate-based assays, monobiotinylated PfRH5FL bait was coated to
wells of streptavidin coated microtiter plates. Binding in the presence of each mAb was probed with pentameric prey proteins of either basigin, PfCyRPA or
PfP113. Data points are the mean, error bars show the SEM. (D) Example graphs of raw SPR data used to make graphs in Figure 3C. Each assay setup was
different for technical reasons. (E) Biotinylated 20-mer peptides overlapping by ten residues and spanning the whole PfRH5 sequence were assayed for mAb
binding by ELISA on streptavidin-coated plates. Only two mAbs (R5.007 and c4BA7) were able to bind any of these overlapping peptides. (F) Binding of anti-
PfRH5mAbs to PfRH5Nt by ELISA. ‘‘Anti-PfRH5FL IgG’’ is PfRH5-vaccinated polyclonal IgG of human origin included as a positive control. Data in panels E and F
are representative of singlicate wells.
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(legend on next page)
Figure S4. PfRH5 Peptide Protection in HDX-MS by R5.004 and R5.016 and Description of Bound R5.004 and R5.016 Fab Fragments, Related
to Figure 4
(A) PfRH5 peptide map showing PfRH5FL protection from deuteration upon R5.004 (left) and R5.016 (right) binding. Secondary structure is shown in gray.
Examples of highly protected peptides are shown in the mass spectra below (NIWRTFQKDEL for R5.004 and IAVDAF for R5.016). Black mass spectra show non-
deuterated peptide, red show the same peptide after unbound (apo) PfRH5FL labeling and blue after PfRH5FL-mAb complex labeling. HDX-MS data for R5.004
were generated following 20 s of labeling and R5.016 after 2 h. (B) 2Fo-Fc electron density maps of the R5.004 and R5.016 variable domains in the bound state,
taken from the PfRH5DNL:R5.004:R5.016 co-complex structure. The electron density map is contoured at 1.0 s. (C) Structural alignments of R5.004 and R5.016
Fab fragments unbound (white) and bound to PfRH5DNL (R5.004 in blue, R5.016 in red). Light chain and heavy chain CDR loops are annotated.
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Figure S5. Investigations into the Effect of R5.011, Related to Figure 5
(A) GIA of 150 mg/mL of R5.016 alone or in combination with 150 mg/mL of each mAb from the green epitope bin (and R5.015 as a negative control) to determine
whether the potentiating effect of R5.011 occurs with similar mAbs. (B) GIA of polyclonal IgG from a PfRH5FL-vaccinated rabbit at 7 mg/mL alone (red) or mixed
(legend continued on next page)
with increasing concentrations of R5.011 (gray). (C) GIAs of nAbs R5.004 and R5.016 alone or with R5.011 as various mAb + Fab fragment combinations. x axis
concentration values are plotted as the concentration of nAb binding site. mAb-mAb combinations are equimolar and mAb-Fab combinations are equimolar in
terms of binding sites. (D) mAb R5.011 is titrated in increasing concentrations into three fixed concentrations of nAb R5.004 or R5.016 to determine the con-
centration at which R5.011 enhancement reaches amaximum. (E) GIA of titration curves of R5.016 + R5.011 combinations in different molar ratios. (F) GIA of total
IgG from a PfRH4-vaccinated rabbit (black), a PfCyRPA-vaccinated rat (yellow), a PfRipr-vaccinated rabbit (orange) and a PfAMA1-vaccinated rabbit (pink) in the
presence of an excess of R5.011 mAb (1.5 mg/mL, all gray data points) showing the maximal extent of R5.011-mediated synergy. The x axis shows the con-
centration of animal-derived IgG only and does not include the R5.011 concentration. (G) GIA of themost potent single human anti-PfRH5mAb (R5.016), themost
potent combination of two human anti-PfRH5 mAbs (R5.016 + R5.011) and of a 1611 bispecific DVD-Ig. The cartoon shows a schematic of the 1611 DVD-Ig
comprising R5.011 and R5.016 variable regions. All data points are the mean of 3 replicate wells, all error bars show the SEM. Parasites used were 3D7 clone
P. falciparum.
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Figure S6. PfRH5 Peptide Protection in HDX-MS by R5.011 and Description of R5.011 Fab Fragment Interaction with PfRH5, Related to
Figure 6
(A) Peptide map showing protection of PfRH5FL from deuteration during R5.011 binding. Secondary structure is shown in gray. An example of a highly protected
peptide is shown in the mass spectra below (peptide NIANS). Black mass spectra show non-deuterated NIANS peptide, red show the same peptide after un-
bound (apo) PfRH5FL labeling and blue after PfRH5FL-mAb complex labeling. HDX-MS data for R5.011 was generated following 20 s of labeling. (B) Structural
(legend continued on next page)
alignment of PfRH5 from the PfRH5DNL:R5.004:R5.016 co-complex (in beige), the PfRH5DNL:R5.011:R5.016 co-complex (in magenta) and the PfRH5 from PDB
entry 4WAT (in light purple), to highlight differences in conformation of the N terminus. (C) Structural alignment of R5.011 Fab fragment unbound (white) and bound
to PfRH5DNL (green). Light chain and heavy chain CDR loops are annotated. (D) 2Fo-Fc electron density map of the R5.011 variable domains in the bound state,
taken from the PfRH5DNL:R5.011:R5.016 co-complex structure. The electron density map is contoured at 1.0 s. (E) SPR sensorgrams of R5.004 (left) or R5.016
(right) binding to PfRH5FL (top) or PfRH5FL-R5.011 Fab fragment complex (bottom). Reported KD and Kon values are the average of three independent
experiments.
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Figure S7. Additional Information from Live-Cell Microscopy Experiments, Related to Figure 7 and Videos S1, S2, and S3
(A) Mean and median early (pre-penetration), late (penetration) and total invasion times of merozoites incubated with 500 mg/mL of R5.011 or a-EBOV. (B) Total
invasion times of merozoites in the presence of neutralizing mAb R5.016 (red), synergistic mAb combination R5.011 + R5.016 (gray), non-neutralizing, non-
potentiating mAb R5.009 (orange) or a-EBOV (black) mAb at the concentrations indicated. Data are representative of n = 9 invasions for R5.009, R5.016 10 mg/mL
and R5.016 + R5.011, n = 12 for R5.016 500 mg/mL, n = 21 for a-EBOV and are presented as box-and-whiskers plots showing the interquartile range and total
range overlaid on individual data points. Solid black lines show the mean for each group. 3D7 clone P. falciparum parasites were used. n.s = non-significant.
